Evidence and desperation in off-label prescribing: recombinant factor VIIa
Field | Value | Language |
dc.contributor.author | Lipworth, W | |
dc.contributor.author | Kerridge, I | |
dc.contributor.author | Little, M | |
dc.contributor.author | Day, R | |
dc.date.accessioned | 2014-06-23 | |
dc.date.available | 2014-06-23 | |
dc.date.issued | 2012-01-01 | |
dc.identifier.citation | Lipworth W, Kerridge I, Little JM, Day R. Evidence and desperation in off-label prescribing: recombinant factor VIIa. BMJ 2012;344:d7926 | en_AU |
dc.identifier.other | http://211.144.68.84:9998/91keshi/Public/File/38/344-7840/pdf/bmj.d7926.full.pdf | |
dc.identifier.uri | http://hdl.handle.net/2123/10788 | |
dc.description.abstract | Wendy Lipworth and colleagues explore why clinicians prescribe recombinant f actor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this matters | en_AU |
dc.language.iso | en_AU | en_AU |
dc.publisher | BMJ | en_AU |
dc.rights | Creative Commons Attribution Licence CC BY-NC 3.0 | en_AU |
dc.title | Evidence and desperation in off-label prescribing: recombinant factor VIIa | en_AU |
dc.type | Article | en_AU |
Associated file/s
Associated collections